Background: Despite historically high rates of herpes zoster among people living with HIV (PLWH), comparative studies of herpes zoster by HIV serostatus are lacking since the advent of combination antiretroviral therapy and availability of zoster vaccine.
BACKGROUND
Varicella-zoster virus is the causative agent of both varicella and herpes zoster diseases. Herpes zoster results from the reactivation of latent virus within dorsal root ganglia. 1 Herpes zoster is a unique vaccine-preventable disease in that the risk of disease is not associated with exposure, but rather with host factors that influence reactivation, especially increasing age and immunosuppression. Declining varicella-zoster virus-specific cell-mediated immunity is believed to explain the increased incidence of herpes zoster in people aged older than 50 years or with immunosuppression. 2, 3 In the era before combination antiretroviral therapy (cART), HIV infection was associated with a 12-to 17-fold increased risk of herpes zoster compared with uninfected adults. 4 The subsequent decline in herpes zoster incidence over time has been attributed to improved immunologic function with cART, but the risk remains elevated, especially when the CD4 T-cell count remains depressed. [5] [6] [7] Furthermore, even with cART, herpes zoster incidence continues to be higher in people living with HIV (PLWH) compared to uninfected individuals. 8 Before late 2017, there was only one licensed vaccine to prevent herpes zoster. The zoster vaccine live (ZVL) was recommended by the Advisory Committee on Immunization Practices (ACIP) in 2008 for use as a one-time vaccination in immune competent adults aged 60 years and older with a warning to avoid in immunocompromised people. 9 This recommendation was based on a large study that showed the vaccine reduced the risk of developing herpes zoster by 51.3%. 10 Despite guidelines for ZVL (the only herpes zoster vaccine available until 2018), rates of vaccination in the United States were low in the general population, being less than 35.0% as of 2015 11 and even lower among HIVuninfected veterans aged 60 years and older, with only 6.4% vaccination coverage as of 2015. 12 The cardinal study evaluating efficacy of the ZVL, the Shingles Prevention Study, excluded immunosuppressed patients because of the vaccine being a live-attenuated vaccine. 10 As a result, the rates of zoster vaccination are even lower in immunocompromised populations, and there is a paucity of literature regarding administration in these populations, including PLWH. However, a review of patients who received ZVL after hematopoietic cell transplant (HCT) (median time to vaccination was 482 and 1323 days for autologous and allogeneic for HCT recipients, respectively) demonstrated no adverse events with ZVL, and the authors concluded that ZVL can be administered to select patients with hematologic malignancy after HCT who are on minimal to no immunosuppressive therapy. 13 Among PLWH, a small study demonstrated that the ZVL was safe and immunogenic in children with a CD4 T cell % $15%. 14 Recently, 2 doses of ZVL were also shown to be safe and immunogenic in adults living with HIV with a CD4 T-cell count $200 cells per microliter. 15 Despite data on safety and immunogenicity, vaccine uptake among PLWH has been low. 16 Lack of or unclear guidelines regarding herpes zoster vaccination in PLWH has been implicated as one reason for low rates of vaccination in PLWH. 16, 17 The ACIP and World Health Organization guidelines do not have a recommendation for zoster vaccination in PLWH, even with CD4 count $200 cells per microliter. 18, 19 The Infectious Disease Society of America guidelines for immunocompromised individuals were corrected to include a recommendation on administration of ZVL to asymptomatic PLWH aged 60 years and older who are VZV-seropositive with a CD4 T-cell count $200 cells per microliter. 20, 21 Similarly, the British HIV association guidelines recommend administration of ZVL to asymptomatic PLWH aged 70 years and older who are VZV-seropositive with a CD4 T-cell count $200 cells per microliter. 22 ZVL is contraindicated when the CD4 T-cell count is ,200 cells per microliter. 20, 21 The objective of this study was to compare rates of herpes zoster incidence and vaccine incidence by HIV status over time. These data will assess the need for specific guidelines for herpes zoster vaccination in HIV.
METHODS

Study Population
The Veterans Aging Cohort Study is a periodically updated prospective observational cohort identified from the US Department of Veterans Affairs that includes .50,000 PLWH and .100,000 uninfected adults. Our study population comprised adults living with and without HIV who were in Veteran's Administration (VA) care between 2002 and 2015.
Outcomes
Annual herpes zoster events were identified based on ICD9 codes (053.0, 053.11, 053.2·, 053.7·, 053.8, and 053.9). Participants with a previous history of herpes zoster were excluded. Herpes zoster vaccine administration was captured using pharmacy data and Current Procedural Terminology code 90736. The only herpes zoster vaccine available during this study period was ZVL.
Covariates were captured both at study start (baseline) and for every fiscal year. Age was recorded in years. HIVspecific covariates were CD4 T-cell count (cells/mL) and HIV-1 viral load (VL) (RNA copies/mL). Virologic suppression was defined as #400 copies per milliliter to allow for a single definition across all years. Descriptive characteristics and comorbidities were defined as in previously published Veterans Aging Cohort Studies. [23] [24] [25] [26] Statistical Analysis
Annual incidence rates [n/1000 and 95% confidence interval (CI)] of first-event herpes zoster and herpes zoster vaccine receipt were determined from fiscal year 2002 (beginning October 1, 2001 ) to fiscal year 2015 (ending September 30, 2015) . Eligible participants for each year were alive at the end of the fiscal year and had a VA outpatient visit within that fiscal year. Results were further stratified by age, CD4 T-cell category, and suppressed/unsuppressed HIV-1 VL. A subanalysis examining sex differences demonstrated no statistically significant differences, but was underpowered. For annual zoster vaccine rates, participants with a previous history of zoster vaccine administration within another year during the study period were excluded from the annual analysis but included in cumulative analyses. Those with a CD4 T-cell count of ,200 cells per microliter were excluded from the zoster vaccine rate analysis. 
RESULTS
Herpes Zoster Events
Between 2002 and 2015, 8017 cases of first-time diagnoses of herpes zoster were reported. Average incidence rates over the study period were markedly higher among PLWH (4749 cases of herpes zoster detected for an average rate 14.1/ 1000) compared with uninfected individuals (3268 cases for an average rate 3.4/1000). From 2002 to 2015, annual rates of herpes zoster decreased among PLWH (17.6-8.1/1000) and increased among uninfected individuals (2.3-4.1/1000). By the end of the study period in 2015, rates remained significantly higher among PLWH compared with uninfected individuals (8.1/1000 vs 4.1/1000, P , 0.001), Table 3 .
At end of study period (2015), the herpes zoster rates were highest among PLWH aged younger than 60 years (8.7/1000) and lowest among uninfected adults aged younger than 60 years (2.9/1000) (Fig. 1A) . In 2015, herpes zoster rates were highest among 50-to 59-year-old PLWH (9.7/1000) and, among uninfected adults, in the 60-to 69-year-old group (5.2/1000). In analyses restricted to PLWH, herpes zoster rates were highest among those with the lowest CD4 T-cell counts (CD4 ,200 cells/mL: 18.0; CD4 201-350: 14.4; CD4 351-500: 7.5; .500: 6.8/1000) and higher among those with unsuppressed compared with suppressed HIV-1 RNA (21.8 vs 7.1/1000). In analyses restricted to virologically suppressed PLWH with CD4 T cell .350 cells per microliter, herpes zoster rates were similar among PLWH aged younger than 60 years and aged 60 years and older (6.6 vs 6.7/1000) but remained higher than that among uninfected adults (Fig. 1B) . The 2015 rates of herpes zoster by CD4 T-cell count strata and virologic suppression and then by HIV serostatus group by different age groups are shown in Tables 3 and 4 , respectively.
Zoster Vaccine Events
From 2006 to 2015, zoster vaccine was administered to 1399 PLWH and 8657 uninfected adults aged 50 years and older. This included the following: 551 veterans between ages 50-59 years, 7440 between ages 60 and 69 years, and 2064 aged 70 years and older. Vaccination rates increased steadily over the study period for both PLWH and uninfected adults (Fig. 2) , with the largest increase in rates of zoster vaccine seen between 2011 and 2012. By 2015, cumulative zoster vaccination was less than half for PLWH compared with uninfected individuals: 62.5 vs 134.3/1000 among aged 50 years and older and 98.7 vs 215.1/1000 among those aged 60 years and older (Fig. 2) .
DISCUSSION
Our study confirms and updates recent analyses showing that herpes zoster rates remain higher in PLWH compared with uninfected adults, despite virologic suppression and higher CD4 T-cell counts with the advent of cART. 7, 8, 27, 28 The striking inverse association between herpes zoster with CD4 T-cell count and viral suppression among PLWH (Table  3 ) emphasizes the importance of early cART initiation in decreasing the burden of herpes zoster. More importantly, we show that PLWH across all age groups have a greater risk of herpes zoster than uninfected adults, with the highest rates among those aged 50-59 years. Interestingly, when the analysis was restricted to those with HIV VL #400 copies per milliliter and CD4 T-cell count greater than 350 cells per microliter, the age differences were attenuated, suggesting that among PLWH, HIV-related immunosuppression is a more important determinant of herpes zoster risk than age. 29 Our study demonstrated that rates of herpes zoster have steadily declined among adults living with HIV. Previous studies have also shown this trend, likely due to higher CD4 T-cell counts at HIV diagnosis, and improved virologic suppression with cART. 7, 8 The effect of vaccination on herpes zoster incidence among adults living with HIV has not been reported. Among adults without HIV, despite the introduction of the herpes zoster vaccine, rates of herpes zoster increased with increasing age, as has been previously reported in the literature. [30] [31] [32] [33] The cause of increasing rates of herpes zoster among adults without HIV is likely multifactorial and may be the result of childhood varicella vaccination resulting in lower exposure among adults to primary varicella and subsequent boosting effect in addition to increasing use and strength of immunosuppressive medications. 33 Despite vaccine availability in the United States since 2006, herpes zoster vaccination in the general population has been low, with the percentage of vaccinated, eligible adults ranging anywhere from 6% to 30%. 11, 12 Indeed, our study showed, among veterans, a cumulative vaccination coverage of 21.5% in uninfected adults aged 60 years and older and rates of ,10.0% among PLWH. There is a lack of published data regarding the use of herpes zoster vaccination among PLWH, although a recent study evaluating zoster vaccination rates at 6 different institution-based clinics (3 VA centers, a Canadian academic center, an university-based clinic, and an urban safetynet hospital) demonstrated zoster vaccine coverage rates anywhere from 1.5% to 42.5% among PLWH. 16 There are many potential reasons underlying the slow uptake of herpes zoster vaccination among PLWH. Lack of knowledge regarding the much higher incidence of herpes zoster in PLWH, safety concerns with ZVL, unclear guidelines, and practical barriers including billing and out-ofpocket costs has been implicated as impediments to herpes zoster vaccination among PLWH. 17 Until recently, the only zoster vaccine available was ZVL, with a stated contraindication for use when CD4 T-cell count is less than 200 cells per microliter. 20, 21 A recent publication has confirmed that 2 doses of ZVL are safe and likely immunogenic in PLWH with a suppressed VL and CD4 T-cell count .200 cells per microliter. 15 A nonlive, adjuvanted, recombinant zoster vaccine (RZV) against herpes zoster was approved in late 2017 for immune competent individuals. 34 The recent approval and rollout of RZV is a stimulus to reinvigorate the push to vaccinate for this preventable disease. The ACIP recommends RZV for immunocompetent adults aged 50 years and older. RZV is a 2-dose vaccine with a reported efficacy in the general population of 97.2%. 34 Furthermore, it retains excellent efficacy in people aged 70 years and FIGURE 1. A, Herpes zoster rates by age and HIV serostatus over study period (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . B, Herpes zoster rates by age and HIV serostatus over study (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) when PLWH restricted to CD4 T cell .350 cells per microliter and HIV-1 RNA #400 copies per milliliter.
older, with protection persisting for at least 4 years, whereas protection declines significantly after ZVL over a similar interval. 35 A phase 1/2 study has already evaluated RZV in PLWH. 36 The study included PLWH on cART with a CD4 T-cell count .200 cells per microliter, cART-naive PLWH with CD4 T-cell count .500 cells per microliter, and PLWH on cART with a CD4 T-cell count between 50 and 199 cells per microliter. RZV was safe and immunogenic compared with placebo, but the study was insufficiently powered to make determinations about safety and immunogenicity among PLWH with a low CD4 T-cell counts or those not on cART. 36 Additional studies are under way to evaluate the safety and immunogenicity of this vaccine in immunocompromised populations (NCT03493776, NCT01767467, NCT02058589, and NCT01798056).
PLWH have diminished immunogenicity to certain vaccinations, and these effects are amplified by lack of viral suppression and low CD4 T-cell counts. [37] [38] [39] [40] Indeed, for many vaccinations, it is advised to wait for the CD4 T-cell count to be .200 cells per microliter or until there is a sustained rise in CD4 T-cell count before vaccinating to improve immune response to vaccination. 41, 42 As the greatest risk of herpes zoster among PLWH is in those with lower CD4 T-cell count and lack of viral suppression, 5, 6, 43 an ideal vaccine candidate would be safe and provide lasting protection even when administered to those with lower CD4 T-cell counts. The immunogenicity of the RZV at age .70 years in the general population 35 may be a signal that this adjuvanted vaccine could provide protection against herpes zoster across a range of CD4 T-cell counts, although more studies are needed.
The strengths of this study include a large cohort for direct comparison of herpes zoster and herpes zoster vaccination rates among PLWH and uninfected adults, in an otherwise similar population. This study does have limitations: we used ICD9 codes to capture clinical events of firsttime zoster and a Current Procedural Terminology code in addition to pharmacy data to capture herpes zoster vaccination and may have missed improperly coded clinical events or vaccination. A previous validation study of Veterans Affairs data in Atlanta demonstrated that ICD9 codes were erroneous (positive predictive value of 0.56) but still predicted true trends in incidence of zoster. 32 The incidence of zoster vaccination may have been underestimated because our methods did not allow for inclusion of those who received vaccination outside of the VA system. Furthermore, we were underpowered to evaluate efficacy of the ZVL due to the low numbers of vaccinated individuals. In addition, data on adverse events or side effects related to administration of ZVL were not readily available. Although our findings are likely generalizable, it is important to point out that the demographic and comorbid diseases in the veteran population may differ from patients who receive care outside Veterans Administration facilities.
In conclusion, this study highlights the continued higher rates of herpes zoster among PLWH compared with uninfected individuals. Rates of herpes zoster are high across all age groups of PLWH and are closely associated with both low CD4 T-cell counts and HIV-1 viremia. Herpes zoster vaccination uptake has been universally low, and rates of vaccination in PLWH are less than half that of uninfected individuals. The roll out of the RZV provides a new opportunity to study this vaccine in PLWH across all age and CD4 T-cell count spectra and develop vaccination guidelines for prevention of herpes zoster in PLWH. 
